Extrapyramidal symptoms (EPS) are the umbrella name for movement side effects produced by medications that block dopamine D2 receptors — most often antipsychotics, but also some antiemetics like metoclopramide and prochlorperazine. The "extrapyramidal" label dates from a time when neurologists divided the motor system into pyramidal (cortical, voluntary) and extrapyramidal (subcortical, automatic) tracts. The basal ganglia sit in that second system, and they are where dopamine blockade does its damage.
EPS is a four-part syndrome — acute dystonia, drug-induced parkinsonism, akathisia, and tardive dyskinesia — produced by dopamine D2 receptor blockade in the basal ganglia, with each subtype arising on a different timescale and responding to different treatments.
Why dopamine blockade produces movement problems
The nigrostriatal dopamine pathway runs from the substantia nigra to the striatum and modulates movement. Antipsychotics block postsynaptic D2 receptors throughout the brain to reduce psychotic symptoms in the mesolimbic pathway, but they cannot selectively avoid the nigrostriatal pathway. Once D2 occupancy in the striatum exceeds roughly 80%, motor side effects become common. This is why the highest-affinity, highest-potency D2 blockers (haloperidol, fluphenazine) produce the most EPS, and why partial agonists (aripiprazole, brexpiprazole, cariprazine) and loose D2 binders (clozapine, quetiapine) produce less.
The four EPS subtypes
1. Acute dystonia
Sudden, sustained muscle contraction. The classic forms are torticollis (neck pulled to one side), oculogyric crisis (eyes locked upward), trismus (jaw locked), and laryngeal dystonia (which is the only acutely dangerous form because it can compromise the airway). Onset is hours to a few days after starting an antipsychotic or after a dose increase. Risk factors include young age, male sex, high-potency D2 blockers, and a personal or family history of dystonia.
Acute treatment is intramuscular benztropine 1–2 mg or diphenhydramine 25–50 mg, both of which reverse the dystonia within minutes. Many emergency departments and inpatient units stock these for exactly this reason. Oral anticholinergic prophylaxis is sometimes added for the first few weeks of high-risk regimens. The NICE schizophrenia guideline (CG178) recommends choosing a lower-EPS-risk agent in patients with prior dystonia.
2. Drug-induced parkinsonism
The clinical picture mirrors idiopathic Parkinson's disease: bradykinesia (slowness), rigidity (often "lead-pipe"), tremor (more often postural than resting), masked facies, micrographia, and shuffling gait. Onset is over weeks to a few months. Older patients are at higher risk. Drug-induced parkinsonism is reversible if the offending dose is reduced, the medication is changed, or an anticholinergic such as benztropine is added — though anticholinergics carry their own cognitive cost, especially in older adults, and amantadine is often preferred when cognition is a concern.
3. Akathisia
An inner restlessness coupled with the urge to move — pacing, shifting from foot to foot, inability to sit still. Akathisia has its own deep-dive article in this series; the short version is that it is one of the most distressing antipsychotic side effects, is frequently mistaken for anxiety or worsening psychosis, and has been linked to medication non-adherence and elevated suicide risk in observational data. Treatment includes lowering the dose, adding propranolol or a benzodiazepine, or switching the antipsychotic.
4. Tardive dyskinesia (TD)
Late-onset involuntary movements — typically of the face, mouth, tongue, fingers, and toes — appearing after months to years of cumulative D2 blockade. Unlike the other EPS subtypes, TD can persist or become permanent. Annual incidence is roughly 4–5% per year on first-generation antipsychotics and 1–3% per year on second-generation agents. Risk rises with age, female sex, diabetes, and a history of acute EPS. Two FDA-approved VMAT2 inhibitors (valbenazine and deutetrabenazine) now provide effective symptomatic treatment; see our TD article for details.
Screening: the AIMS exam
The Abnormal Involuntary Movement Scale (AIMS) is a brief structured exam that scores movements in seven body regions plus global severity. Most guidelines recommend an AIMS at baseline and at least annually for any patient on long-term antipsychotic treatment. In practice, AIMS exams are skipped at most US visits. If your prescriber has not done one, ask.
Risk by medication
- Highest EPS risk: haloperidol, fluphenazine, perphenazine, trifluoperazine
- Moderate-high: risperidone (especially >6 mg), paliperidone, lurasidone, ziprasidone
- Moderate (especially akathisia): aripiprazole, brexpiprazole, cariprazine
- Low: olanzapine, asenapine, lumateperone
- Lowest: clozapine, quetiapine
This ordering is approximate and reflects pooled trial and observational data summarised in reviews such as the Lancet network meta-analyses by Huhn and colleagues. Individual response varies enormously.
Differential diagnoses to keep in mind
EPS can mimic — and be mimicked by — several other conditions:
- Anxiety and agitation (often confused with akathisia)
- Catatonia (which can include rigidity and posturing but has a different pattern)
- Idiopathic Parkinson's disease (especially in older patients)
- Wilson's disease, Huntington's disease, and other primary movement disorders
- Serotonin syndrome and neuroleptic malignant syndrome (both medical emergencies)
Severe muscle stiffness with high fever, confusion, or markedly elevated heart rate or blood pressure can signal neuroleptic malignant syndrome. New laryngeal dystonia (tight throat, trouble breathing) also requires emergency evaluation.
Practical principles for managing EPS
- Use the lowest effective antipsychotic dose.
- Choose lower-risk agents in patients with prior EPS or known risk factors.
- Screen with the AIMS at least yearly.
- Treat acute dystonia immediately with IM anticholinergic.
- For parkinsonism: lower dose, switch agent, or add amantadine/anticholinergic.
- For akathisia: lower dose, add propranolol or short-term benzodiazepine, or switch.
- For TD: refer for VMAT2 inhibitor assessment; do not abruptly stop the antipsychotic without a plan.
The bottom line
EPS is treatable when it is named. The main reason patients suffer with movement side effects is that no one asks. Knowing the four subtypes, the timescales they appear on, and the medications most likely to cause each turns EPS from a hidden burden into a problem with concrete solutions. For more, see our akathisia deep dive, tardive dyskinesia, and the NIMH schizophrenia overview.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.